Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 9
Submit an article Journal homepage
181
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

A patient with refractory high-grade B-cell lymphoma and rapid progression under CAR-T-cell therapy was successfully salvaged with inotuzumab- ozogamicin

T. Strüßmanna Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GermanyCorrespondence[email protected]
View further author information
,
R. Wäscha Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GermanyView further author information
,
F. Scherera Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany;b German Cancer Consortium (DKTK) partner site Freiburg and German Cancer Research Center (DKFZ), Heidelberg, GermanyView further author information
,
J. A. Muttera Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany;c Faculty of Biology, University of Freiburg, Freiburg, GermanyView further author information
,
D. Pfeifera Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GermanyView further author information
,
I. Bartscha Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GermanyView further author information
,
S. Gieslera Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GermanyView further author information
,
G. Graziania Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GermanyView further author information
,
J. Duystera Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GermanyView further author information
,
J. Finkea Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GermanyView further author information
&
R. Marksa Department of Medicine I, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, GermanyView further author information
 show all
Pages 2260-2262 | Received 21 Mar 2022, Accepted 30 Apr 2022, Published online: 20 May 2022

References

  • Maruyama D, Watanabe T, Maeshima AM, et al. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/Ifosfamide, Etoposide, and Cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt Lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol. 2010;92(5):732–743.
  • McClure RF, Remstein ED, Macon WR, et al. Adult B-Cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005;29(12):1652–1660.
  • Braziel RM, Arber DA, Slovak ML, et al. The Burkitt-like lymphomas: a southwest oncology group study delineating phenotypic, genotypic, and clinical features. Blood. 2001;97(12):3713–3720.
  • Fehse B, Badbaran A, Berger C, et al. Digital PCR assays for precise quantification of CD19-CAR-T cells after treatment with axicabtagene ciloleucel. Mol Ther Methods Clin Dev. 2020;16:172–178.
  • Scherer F, Kurtz DM, Newman AM, et al. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med. 2016;8(364):364ra155.
  • Kurtz DM, Scherer F, Jin MC, et al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphoma. J Clin Oncol. 2018;36(28):2845–2853.
  • Rossi D, Diop F, Spaccarotella E, et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood. 2017;129(14):1947–1957.
  • Rivas-Delgado A, Nadeu F, Enjuanes A, et al. Mutational landscape and tumor burden assessed by cell-free DNA in diffuse large B-cell lymphoma in a population-based study. Clin Cancer Res. 2021;27(2):513–521.
  • Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547–555.
  • Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753.
  • Sangha R, Davies A, Dang NH, et al. Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. J Drug Assess. 2017;6(1):10–17.
  • Fayad L, Offner F, Smith MR, et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013;31(5):573–583.
  • Ceolin V, Brivio E, Rheingold SR, et al. Potential impact of treatment with inotuzumab ozogamicin on chimeric antigen receptor T-Cell therapy in children with relapsed or refractory acute lymphoblastic leukemia. Blood. 2021;138(Supplement 1):3824–3824.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.